Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Financial PostAugust 31, 2026
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT …
Where this sits on TrendsMap
This story is filed under New York, which has seen 334 stories in the last 30 days — putting it in the top 10% of the 85 territories we currently cover. We hold 2111 politics stories in total, and 1248 from Financial Post.
This is a summary of reporting by Financial Post. Read the full story at the source.
Read full storyPredictions (0)
No predictions yet on this story — be the first to start one.
Comments (0)
GU
posting as a guest
Create a free account to comment under your own name and earn Pulse.